JP2006213628A - Antistress agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a safety and easy to take and ingest antistress agent, a pharmaceutical, a food or drink and a flavoring composition effectively preventing or ameliorating various symptoms accompanied by a stress. <P>SOLUTION: The antistress agent comprises myrcenol as an active ingredient. The myrcenol is an unsaturated aliphatic higher alcohol with 10 carbon atoms and especially derived from hops and has a GABA receptor activating potential. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to an anti-stress agent using mircenol as an active ingredient. In addition, the present invention relates to a pharmaceutical, a food or drink, or a fragrance composition that contains, as a component, myrcene, which is produced by oxidation of myrcene contained in hops, etc., and prevents or reduces mental and physical symptoms caused by stress. It is.

In modern societies that are sophisticated, complex and active 24 hours a day, people are exposed to various types of physical, chemical, psychological and social stress. In particular, there are many psychological factors that constitute stress for modern people living in complex human relationships.
Various studies have been conducted on psychological stress and the various symptoms it causes. For example, when psychological stress is detected in the cerebrum, it is reported that the release of noradrenaline is enhanced in a wide range of brain regions, which triggers psychiatric symptoms such as anxiety and tension (Non-patent Document 1). . If stress persists for a long time, it may affect various organs throughout the body, resulting in severe psychosomatic disorders, depression, gastric ulcers, hypertension and the like.

  Currently, drugs used for the purpose of stress reduction or prevention or treatment of diseases caused by stress are mainly benzodiazepine anxiolytics and hypnotics. The GABA nervous system in the brain is composed of two receptors, the GABAa receptor and the GABAb receptor. The GABAa receptor, which is thought to be the site of action of benzodiazepine anxiolytics and hypnotics, uses Cl channels. It has a benzodiazepine binding site as the center and also forms a barbital binding site. It has been reported that when the benzodiazepine binding site and the barbital binding site are stimulated, the affinity of the GABAa receptor for GABA increases (Non-patent Document 2).

In addition, it has been reported that when the GABA nervous system in the brain is activated, a stress relieving action is expressed. Gastric ulcers develop when rats are exposed to cold restraint stress (4 ° C., 2 hours). The occurrence of this gastric ulcer is dose-dependently suppressed by intraventricular administration of GABA (5, 10, 20, 50 μg) and GABAa receptor agonist (Muscimol) (5, 10 μg), It has been reported that a GABA receptor antagonist (antagonist) bicuculine (40 μg) eliminates the suppression of stress ulcer by GABA (Non-patent Document 3). In addition, muscimol, a GABAa receptor agonist, and aminooxy-acetic acid (a GABA deaminase inhibitor) that increases GABA concentration in the brain can cause increased exercise and gastric ulcers in rats. It has also been reported that it is suppressed (Non-Patent Document 4). Thus, the GABA nervous system in the brain plays an important role in stress relaxation.

  Benzodiazepine anti-anxiety drugs and sleeping pills are relatively safe drugs, but because they have addictive and side effects, it is not preferable to take them frequently against temporary stress in daily life. In addition, if the use is interrupted after taking the medicine, rebound may occur and the symptoms may be worsened, which is not an ideal anti-stress agent.

  In this way, taking into consideration the serious impact on the living body not only in terms of mental health, but also in terms of mental health, which increases the stress load in modern society, it is truly effective and should be taken with peace of mind. Development of safe anti-stress agents that can be used is desired. In particular, from a preventive standpoint, the development of an anti-stress agent that can be used for food and luxury goods is desired.

By the way, hop is widely known as a perennial mulberry plant (scientific name: Humulus luplus) native to Europe, but in general, its fruit (mature female flower) is called hop. Hops are one of the ingredients for making beer and have been effective for the bitterness and fragrance unique to beer and have been ingested by people for many years. Such bitterness and aroma are brought about by the lupulin portion of the hop (yellow granules formed at the root of the inner pod of the fruit).
As a hop effect, many physiological effects such as a sedative effect, a sleep / sleep effect, an appetite increase, a healthy stomach effect, and a diuretic effect are known. Among these, for the sedative action of hops, for example, a plant having the sedative action in the composition of sleep disorder comprising a genus Valeriana or an extract thereof, a plant having a sedative action or an extract thereof and γ-aminobutyric acid, A composition for sleep disorder that is hop is disclosed (see Patent Document 1). However, the causative substances related to such actions are not clarified, and it is possible to grasp that the sedation action immediately has the effect of reducing the stress as having the same dimension. Is not what has been revealed.
JP 2003-183174 A Tanaka Masatoshi, Metabolism, vol.26, p122-131, 1989 DG Nicholls, Amino Acids as Neurotransmitter, in “Proteins, Tensmitters and Synapses.” Blackwell Scientific Publication, Oxford, p. 155-185 (1994) KP Bhargava, GP Gupta and MB Gupta, “Central GABA-ergic mechanism in stress-induced gastric ulceration”, British Journal of Pharmacology, vol.84, p.619-623 (1985) Psychopharmacology 89: 472-476 (1986)

  The present invention can effectively prevent or reduce various physical symptoms associated with stress, and is a safe anti-stress agent that is easy to take and ingest, and a composition or a function that contains an active substance as the anti-stress agent The purpose is to provide food. Another object of the present invention is to provide an anti-stress agent that activates the GABA receptor and suppresses or prevents physical symptoms associated with stress.

In order to develop an effective and safe anti-stress agent, the present inventors have conducted trial and error studies on various compounds, and alcohol, particularly fruit wine, sake, shochu or whiskey fragrance components are anti-stress. A patent application was filed after obtaining the knowledge of showing the action (Japanese Patent Application No. 2003-171286). Furthermore, the present inventors are said that beer is a stress relieving agent that relieves mental tension and relieves mental fatigue as the research proceeds (Internet homepage: http: //www.brewers.or. jp / 100ka / alacarte / kennko.htm), we studied the aroma component of beer, and obtained an unexpected finding that one of its components, milsenol, exhibits anti-stress action.
The present invention has been made based on such new findings.

More specifically, the present inventors screened substances having an anti-stress action, using as an index the enhancing action on the GABA response of Xenopus oocytes expressing the GABA receptor. As a result, the present inventors have found that the aroma component of beer, particularly myrsenol, has an action of enhancing the GABA response of the GABA receptor. Furthermore, the present inventors have conducted in vivo pharmacological studies using a prolongation effect on sleep time as an index when pentobarbital, which is a GABA receptor antagonist, is administered to mice, and are aroma components of beer. Milsenol was found to significantly prolong the sleep time induced by pentobarbital. As described above, since the brain GABA nervous system plays an important role in stress relaxation, it is clear that the aroma component of beer milsenol has an action to relieve stress through activation of brain GABA receptors. It was made.
In addition, milsenol is a beer fragrance component that has been loved by people for many years, and milsenol has been approved as a food additive (designated additive), so there are no safety issues. In the case of an anti-stress agent containing milsenol in the form of a pharmaceutical product, food or drink, or a fragrance composition, it can be provided in a non-alcoholic situation, so that it can be easily and easily taken under any circumstances when taking or ingesting. There is also an advantage that it can be ingested.

That is, the present invention
(1) An anti-stress agent comprising mircenol as an active ingredient,
(2) The antistress agent according to (1) above, wherein myrsenol is derived from hops,
(3) The antistress agent according to (1) or (2) above, which has a GABA receptor activation effect,
(4) A medicinal product having anti-stress action, characterized by containing myrsenol as an active ingredient,
(5) Food / beverage products having anti-stress action, characterized by containing myrsenol as an active ingredient,
(6) A fragrance composition having an anti-stress action, characterized by containing mircenol as an active ingredient, and (7) a method for reducing or alleviating stress, characterized by ingesting mircenol,
About.

The antistress agent containing milsenol according to the present invention as an active ingredient can effectively prevent and reduce stress through activation of GABA receptors, particularly activation of the GABA nervous system in the brain. As a result, the anti-stress agent of the present invention can suppress, treat or prevent physical symptoms associated with stress.
Moreover, since the anti-stress agent according to the present invention contains milsenol, which is approved as a food additive (designated additive), as an active ingredient, it is excellent in safety and has no special restrictions in use. Has the advantage.
Furthermore, the anti-stress agent according to the present invention has the advantage that it is easy to take or ingest anywhere, and in particular, the anti-stress agent according to the present invention is a functional food such as a drink or a jelly-like food. In this case, it can be used on a daily basis in order to prevent and / or reduce stress.

The present invention provides an anti-stress agent containing milsenol as an active ingredient, and milsenol used in the present invention is one of higher aliphatic alcohols having a structure represented by the following formula I. Thus, it is a compound that is widely known as a perfume compound and approved as a food additive.

  Milsenol contained in the antistress agent according to the present invention may be naturally derived or a synthetic product. Moreover, since what satisfy | fills the specification of a food additive can be obtained from the market as a brand name Milsenol (made by Taiyo Inc.) etc., this can also be used.

As a natural source, there is one derived from hop (scientific name: Humulus luplus), a mulberry perennial plant native to Europe. Hops essential oil component is as many as 250 types, but it contains a large amount of two main compounds, Humulene and Myrcene. The essential oil component of hops is easily oxidized, and the above myrcene is oxidized to myrsenol. In beverages made from hops, such as beer, beer-taste beverages, Hoppy (registered trademark), myrcene, an essential oil component, is oxidized into hydrophilic myrsenol during hop storage or wort boiling, Present in the final product. Therefore, the myrsenol contained in the antistress agent according to the present invention prepares a concentrate of a beverage that is a final product made from hops such as beer, and the concentrate is directly contained in the antistress agent according to the present invention. You can also. For the preparation of the concentrate, for example, a known method such as pentane extraction described in JP-A No. 2003-171286 may be used. Moreover, you may refine | purify the concentrate obtained as mentioned above, and may make the anti-stress agent which concerns on this invention contain the myrsenol as the refined | purified substance. For the purification of the concentrate, a known method such as purification by column chromatography can be used.
As synthetic myrsenol, for example, Chemistry Letters (Chemistry)
Letters) pp. 157-160 1986, Chemical Industry (Chem. Ind) page 370, 1976, milsenol can be synthesized by the method described in JP-A-59-118728. Furthermore, commercially available products that can be obtained from the market can be used, but in the present invention, those satisfying the provisions of food additives can be suitably used and are not subject to any restrictions.

  In the antistress agent according to the present invention, only myrsenol may be contained as a single active ingredient, or may be contained in a state where it is mixed with a plurality of other ingredients. In particular, synthetic products may contain a small amount of cis or trans osimenol in addition to myrcenol. It can be purified by column chromatography or the like to obtain pure myrsenol, but it can also be used as it is.

  The anti-stress agent containing milsenol according to the present invention as an active ingredient refers to a substance having an anti-stress action for reducing or alleviating stress and maintaining homeostasis in vivo, or a composition containing the substance. In other words, the anti-stress agent in the present invention refers to a substance that causes a reaction that a living body tries to protect or adapt to stress, or a composition containing the substance. Here, stress refers to strain that occurs in the mind and body when a stimulus (stressor) that normally causes stress is applied to the living body.

Stressors include physical stimuli such as cold, weather changes, radiation and noise; chemical stimuli such as drugs, vitamin deficiencies and oxygen deficiencies; biological stimuli such as bacterial infections; Psychological stimuli such as tension, anxiety and fear arising from human relationships in society and home.
Therefore, the anti-stress agent according to the present invention is useful for preventing stress, promoting recovery from stress, and the like, and can prevent, ameliorate, or cure medical symptoms caused by stress.

  Medical symptoms resulting from the stress include: (a) cardiovascular diseases such as arteriosclerosis, ischemic heart disease (angina pectoris, myocardial infarction), essential hypertension, cardiac neuropathy, arrhythmia, b) Respiratory diseases such as bronchial asthma, hyperventilation syndrome, nervous cough, (c) peptic ulcer, ulcerative colitis, irritable bowel syndrome, anorexia nervosa, neurogenic vomiting, abdominal distension Digestive system diseases such as dysphagia, air swallowing, (d) endocrine metabolic diseases such as obesity, diabetes, psychogenic polyphagia, Graves' disease, (e) migraine, myotonic headache, autonomic nerve Nervous system diseases such as ataxia, (f) Urinary tract diseases such as nocturnal enuresis, impotence, hypersensitive bladder, and (g) osteomuscular diseases such as rheumatoid arthritis, systemic myalgia, spinal hypersensitivity Can be mentioned.

  In addition, medical symptoms caused by the stress include (h) dermatologic diseases such as neurodermatitis, alopecia areata, hyperhidrosis, eczema, (i) Meniere syndrome, pharyngeal head foreign body sensation Diseases in the otolaryngology region such as symptom, deafness, tinnitus, motion sickness, stuttering, (j) diseases in the ophthalmology region such as primary glaucoma, eye strain, blepharospasm, eye hysteria, (k) Gynecological diseases such as dysmenorrhea, amenorrhea, menstrual abnormalities, functional uterine bleeding, menopause, insensitivity, infertility, (l) orthostatic dysregulation, recurrent umbilical colic, psychogenic Diseases in the pediatric field such as fever and night wonder, (m) pre- and post-surgical conditions such as intestinal adhesions, dumping syndrome, frequent surgery (polysurgery), neuroplasty after plastic surgery, and (n) outbreaks Glossodynia, certain types of stomatitis, halitosis, abnormal salivation, masseter muscle che Click, and diseases of the oral cavity region, such as denture neurosis, (o) neurosis, can also be mentioned such as (p) depression.

  The anti-stress agent according to the present invention can be used as a pharmaceutical or a functional food. When the antistress agent of the present invention is used as a pharmaceutical product, the pharmaceutical product may be in any dosage form as long as oral administration or parenteral administration is conveniently performed. Examples of pharmaceutical dosage forms according to the present invention include injections, infusions, powders, granules, tablets, capsules, enteric solvents, troches, liquids for internal use, suspensions, emulsions, syrups, liquids for external use, poultices. Nasal drops, ear drops, eye drops, inhalants, ointments, lotions, suppositories and the like. Moreover, in this invention, according to the symptom, the pharmaceutical agent based on this invention of the said dosage form can be used individually or in combination, respectively.

In the pharmaceutical product according to the present invention, the pharmaceutical agent such as excipient, binder, disintegrant, lubricant, flavoring agent, stabilizer, solubilizer, etc. is added to myrcenol as the main agent according to the type of dosage form of the formulation. Known additives that can usually be used in the field of pharmaceutical technology can be added.
More specifically, when the pharmaceutical product according to the present invention is a solid preparation such as capsule, tablet, powder or granule, for example, excipients such as lactose, glucose, sucrose, mannitol; starch, alginic acid Disintegrants such as soda; lubricants such as magnesium stearate and talc; binders such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin; surfactants such as fatty acid esters; additives such as plasticizers such as glycerin It can be contained. When the pharmaceutical product according to the present invention is a liquid preparation, for example, sugars such as sucrose, sorbit and fructose; glycols such as polyethylene glycol and propylene glycol; oils such as sesame oil, olive oil and soybean oil; p- Additives such as preservatives such as hydroxybenzoates can be included in the formulation. In the case of a liquid formulation, the pharmaceutical product according to the present invention may be a formulation in which milsenol, which is an active ingredient, is dissolved at the time of use.
The ratio of myrcenol to be blended in the preparation as described above is not particularly limited, but usually, 100 parts by weight of the preparation contains 0.01 to 100 parts by weight, preferably 0.1 to 50 parts by weight. Prepare as follows. The pharmaceutical agent according to the present invention can itself be easily produced according to a method well known or commonly used in the field of pharmaceutics.

The administration route of the pharmaceutical agent according to the present invention is not particularly limited, and may be either oral administration or parenteral administration. Among these, it is preferable from the viewpoint of ease of taking that the pharmaceutical according to the present invention can be administered orally.
Moreover, since the dosage of the pharmaceutical agent according to the present invention varies depending on the administration route, dosage form, severity of patient symptoms, age or weight, etc., it cannot be generally stated. Therefore, a preparation containing about 5 to 200 mg of myrsenol per capsule is prepared, and the capsule is about 1 to 10 capsules per day, preferably about 1 to 6 capsules per day, depending on the patient. It may be administered separately.

  When the anti-stress agent of the present invention is used as a functional food, the form may be the same as that of the aforementioned pharmaceutical preparation. Moreover, the said foodstuffs can also be made into processing forms, such as a natural liquid food, a semi-digested-type nutrition food or a component nutrition food, or a drink. Furthermore, the functional food according to the present invention may be an easily soluble preparation in which myrsenol is added to an alcoholic beverage or mineral water at the time of use. More specifically, the functional food according to the present invention containing myrcenol includes, for example, confectionery such as biscuits, cookies, cakes, candy, chocolate, chewing gum, Japanese confectionery; bread, noodles, rice, tofu or processed products thereof Fermented foods such as sake and medicinal liquor; Seasonings such as mirin, vinegar, soy sauce, miso and dressing; Livestock farming foods such as yogurt, ham, bacon, sausage and mayonnaise; A form of a beverage such as a fruit juice beverage, a soft drink, a sports beverage, a jelly-like beverage, an alcoholic beverage, tea, coffee or cocoa; Although the ratio of myrcenol in the food and drink is not particularly limited, it is usually prepared so that 100 parts by weight of food contains 0.0001 to 100 parts by weight, preferably 0.01 to 10 parts by weight. To do.

  In addition, the functional food according to the present invention is prepared on the spot by adding the antistress agent of the present invention to any food during cooking for hospital meals, for example, under the control of a dietitian based on a doctor's meal. It can also be given to patients in the form of functional foods. The anti-stress agent of the present invention may be liquid or solid such as powder or granule.

  The functional food according to the present invention may contain auxiliary ingredients commonly used in the food field. Examples of the auxiliary component include lactose, sucrose, liquid sugar, honey, magnesium stearate, oxypropylcellulose, various vitamins, trace elements, citric acid, malic acid, fragrance, and inorganic salt.

The functional food according to the present invention may be taken when a stress load is expected, or when a stress load is predicted, for example, during physical labor, mental work, or sports. Moreover, you may use regularly in order to measure prevention or reduction of stress.
The intake of the functional food according to the present invention varies depending on the stress state, age, sex, etc. of the person who takes it. About 1 to 1000 mg, preferably about 5 to 500 mg. It is good to take this several times a day.

  The pharmaceutical or functional food according to the present invention can be used in combination with other anti-stress agents, vitamins or hormones or other nutrients, or trace elements or iron compounds. For example, when the functional food according to the present invention is a drink, if desired, it can be given a taste of a favorite beverage by mixing other physiologically active ingredients, minerals, hormones, nutritional ingredients, flavoring agents, etc. Is preferable.

  Furthermore, since the anti-stress agent according to the present invention contains the aromatic component myrsenol as an active ingredient, it can be suitably used as a perfume composition. Examples of the fragrance composition include fragrance compositions for various space sprays (for example, incense, indoor fragrance, car interior fragrance, and deodorant), and cosmetic fragrance compositions (for example, perfume, colon, shampoo and rinse). , Skin care, body shampoo, body rinse, body powders, bath preparations, lotions, creams, soaps, dentifrices, aerosol products, etc., pharmaceutical and quasi-drug fragrance compositions (eg, skin preparations, inhalation) Agent). As described above, the antistress agent of the present invention has various uses, but is not limited to the uses described in the present specification.

〔Example〕
EXAMPLES Next, although an Example demonstrates this invention further, the scope of the present invention is not limited to these.

Extraction from beer 150 ml of commercially available beer (trade name “MALT'S” manufactured by Suntory Ltd.) was extracted with 50 ml of pentane. The extracted solution was distilled off pentane under reduced pressure using a rotary evaporator, and 0.2 ml of ethanol was added to the resulting residue to dissolve it.
The obtained solution was taken with a capillary tube, and compared with commercially available mirsenol (trade name: Milsenol Taiyo Kogyo Co., Ltd.) and subjected to TLC development (developing solvent: 80:20 mixed solvent of hexane and ether), the same as mirsenol. A spot was recognized at the position of.

In Vitro GABA Receptor Activation Action of Milsenol Xenopus oocytes were used as experimental materials. GABA receptor mRNA synthesized based on bovine brain cDNA was injected into the oocyte to express the GABA receptor on the egg surface. Oocytes were maintained in normal frog Ringer's solution (115 mM NaCl, 1 mM KCl, 1.8 mM CaCl2, 5 mM Tris, pH 7.2). Generation | occurrence | production of the inhibitory potential by GABA (0.25 micromol) was measured by the voltage clamp method using voltageclamping amplifier (CEZ-1100; Nihon Koden Kogyo).
Samples were the aroma components of beer obtained in Example 1 (addition concentration: 1 μl / ml) and the following five types (addition concentration: 0.2 μl / ml). The samples used are as follows. Hop essential oil 1 (manufactured by Taiyo Inc.) (shown as Hop oil Perle in FIG. 1), Hop essential oil 2 (produced by Taiyo Inc.) (shown as Hop oil Hall Magnum in FIG. 1), Milsenol (manufactured by Taiyo Inc.) , Myrsen (manufactured by Taiyo Inc.), humulene (α-Humulene) (manufactured by Taiyo Inc.).

  The results are shown in FIG. As an index, the potentiating effect on the inhibitory potential by GABA of the sample was used. The results were expressed as the% increase in inhibitory potential when GABA and the sample were used in combination, with the inhibitory potential generated when GABA (0.25 μM) alone was added as 100. As is clear from FIG. 1, among the samples evaluated, the pentane extract component of beer, hop essential oil 1, hop essential oil 2, myrsenol and myrcene enhanced the GABA response of the GABA receptor. It was found that there is a strong enhancing action.

Examination of dose dependency The dose dependency of myrcenol, which showed strong activity in Example 2, was examined. The test method is exactly the same as in Example 2. The GABA concentration was 0.25 μM, and the sample concentration was 0.01-0.2 μl / ml. The result is shown in FIG. As evident from FIG. 2, myrcenol enhanced the GABA response of GABA receptors up to 290%. The results shown in FIG. 2 show that when the inhibitory potential generated when GABA (0.25 μM) is added alone is 100, the inhibitory potential when GABA and milsenol are used in combination is Expressed as a percentage.

Potentiating effect of mircenol on pentobarbital-induced sleep Test animals were ddy male mice (8 weeks old) purchased from Shimizu Experimental Materials Co., Ltd., and used for experiments after 1 week of preliminary breeding. Breeding conditions set to room temperature 23 ± 2 ° C, humidity 55 ± 5%, aspiration 12-15 times / hour (all fresh), lighting time (12 hours / day, 7am on, 7pm off) In the breeding room, 5 animals were raised in polyisopentene cages (manufactured by CLEA Japan, Inc.). The feed was solid feed CE-2 (Nippon Claire Co., Ltd.), and drinking water was freely consumed.
Mice were orally administered to mice at 50 mg / kg, 100 mg / kg, and 150 mg / kg of mircenol (manufactured by Taiyo Kogyo Co., Ltd.) dissolved in olive oil. In each group, 5 mice were used, and 30 minutes later, pentobarbital dissolved in physiological saline was intraperitoneally administered so that the dose was 50 mg / kg, and the sleep time was measured. The sleep time was defined as the time from the disappearance of the right-angle reflex to the recovery.
The results are shown in FIG. 3, and the experimental results shown in FIG. 3 are expressed as an average value ± standard error. As is clear from FIG. 3, mircenol prolonged the sleep time by pentobarbital in a dose-dependent manner.

[Formulation Example 1]
Capsule a. Formula (per 500mg)
Myrsenol 5mg
Lactose 493mg
Magnesium stearate 2mg
b. Production Method According to the above formulation, myrceneol and lactose were mixed, and after tableting and pulverized, a prescribed amount of magnesium stearate was mixed. Capsules containing 5 mg of myrsenol in one capsule were prepared by filling the mixture into No. 2 capsules in 500 mg increments.

[Formulation Example 2]
Drink a. Formulation Milsenol 5g
DL-sodium tartrate 0.1g
Succinic acid 9mg
800g liquid sugar
Citric acid 12g
Vitamin C 10g
Fragrance 12ml
1g potassium chloride
Magnesium sulfate 0.5g
b. Manufacturing method According to the prescription, dissolve the above components in 8 L of distilled water, add distilled water to make a total volume of 10 L, pass through a 0.22 μm sterilization filter, and aseptically fill 100 ml of brown bottles, 50 mg per agent A drink containing milsenol was prepared.

  The anti-stress agent of the present invention is useful as a pharmaceutical, a functional food, or a fragrance composition because it helps to reduce stress and can prevent or cure various symptoms associated with stress.

It is a graph which shows the GABA receptor activation effect | action using the Xenopus egg cell of the various aromatic components contained in the pentane extract from beer, myrsenol, and a hop. It is a graph which shows the dose dependence of the GABA receptor activation effect of myrsenol. It is a graph which shows the influence which it has on the sleep time by the pentobarbital at the time of orally administering a milsenol to a mouse | mouth.

Claims (7)

  An anti-stress agent comprising mircenol as an active ingredient.   The anti-stress agent according to claim 1, wherein myrsenol is derived from hops.   The antistress agent according to claim 1 or 2, which has a GABA receptor activating action.   A pharmaceutical product having an anti-stress action, characterized by containing mirsenol as an active ingredient.   A food or drink product having an anti-stress effect, characterized by containing mirsenol as an active ingredient.   A fragrance composition having an anti-stress action, characterized by containing mirsenol as an active ingredient. A method of reducing or alleviating stress, characterized by ingesting myrsenol.